Thoratec and HeartWare mentioned positively at Canaccord
Canaccord's LVAD survey indicates better than expected market growth. The firm expects Thoratec (THOR) and HeartWare (HTWR) to grow faster then their estimates and sees upside to Thoratec's Q1 LVAD unit volume. The firm raised Thoratec's price target to $42 from $35 and HeartWare's to $56 from $50. :theflyonthewall.com
Add to My Watchlist
What is My Watchlist?